United Kingdom Cardiometabolic Disease Market Insight
The United Kingdom Cardiometabolic Disease Market is growing at an 10.5% CAGR, driven by rising cardiovascular, diabetes, and obesity cases, NHS access, and increasing adoption of advanced therapies, with AstraZeneca improving treatment effectiveness, safety, and long-term outcomes
United Kingdom Cardiometabolic Disease Market Insights Forecasts to 2035
- The United Kingdom Cardiometabolic Disease Market Size Was Estimated at USD 49.4 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 10.5% from 2025 to 2035
- The United Kingdom Cardiometabolic Disease Market Size is Expected to Reach USD 134.1 Billion by 2035
Notable Insights for United Kingdom Cardiometabolic Disease Market
- By product type, antidiabetic drugs dominated, accounting for approximately 35–40% share in 2024, driven by increasing prevalence of type 2 diabetes and widespread use of GLP-1 receptor agonists.
- By disease type, cardiovascular diseases dominated, holding approximately 45–50% share, due to high incidence of hypertension, coronary artery disease, and heart failure.
- Approximately 30–35% of the UK adult population is affected by cardiometabolic conditions, including diabetes, obesity, and cardiovascular diseases.
- The UK accounts for approximately 15–18% of Europe’s cardiometabolic disease market, with over 80% of patients receiving treatment through NHS services, supporting high treatment accessibility.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Cardiometabolic Disease Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Cardiometabolic Disease Market
- AstraZeneca
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Pfizer Inc.
- Merck & Co.
- Novartis AG
- Boehringer Ingelheim
- Amgen Inc.
- GlaxoSmithKline
- Others
Recent Developments:
- In May 2024: Novo Nordisk reported significant growth in GLP-1 therapy sales, with diabetes products increasing around 30%, reflecting strong global demand and supporting cardiometabolic disease management.
- In February 2023: AstraZeneca received EU approval for dapagliflozin to treat heart failure across full ejection fraction ranges, improving cardiovascular outcomes and reducing hospitalization risks in cardiometabolic patients.
Market Segmentation:
United Kingdom Cardiometabolic Disease Market, By Product Type
- Antidiabetic Drugs
- Antihypertensive Drugs
- Lipid-Lowering Drugs
- Anti-Obesity Drugs
- Others
United Kingdom Cardiometabolic Disease Market, By Disease Type
- Cardiovascular Diseases
- Diabetes
- Obesity
- Metabolic Syndrome
United Kingdom Cardiometabolic Disease Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Cardiometabolic Disease Market is expected to grow steadily due to increasing disease burden and rising demand for integrated treatment approaches. Experts highlight that combination therapies, GLP-1 receptor agonists, and SGLT2 inhibitors will dominate the market. With strong NHS support and growing awareness, demand for effective, long-term cardiometabolic disease management solutions is expected to increase, ensuring sustained market growth.